

# Understanding NAS - a neonatologist's perspective

Maya Balakrishnan, MD, CSSBB

AHCA External Quality Review meeting

11/8/17



# Disclosure statement

- I have no relevant financial relationships with manufacturers of any commercial products or providers of commercial services discussed in this activity.
- I do not intend to discuss an unapproved or investigative use of a commercial product or device in my presentation.



*“I just don’t understand...”*



# Objectives

1. Understand the epidemiology & impact
  2. Describe an interdisciplinary model of care
  3. Discuss opportunities for improved management
-

# NAS


## Nonspecific signs & symptoms of drug withdrawal in infants with in-utero exposure

Opioids	CNS stimulants	CNS depressants
morphine methadone buprenorphine  oxycodone  heroin	methamphetamines amphetamines SSRIs  SNRIs	benzodiazepines barbiturates


***Neonates are not “addicted” or psychologically dependent***

1. Wiles JR, Isemann B, Mizuno T, Tabangin ME, Ward LP, Akinbi H, et al. Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study. *J Pediatr*. 2015.
2. Nayeri F, Sheikh M, Kalani M, Niknafs P, Shariat M, Dalili H, et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. *BMC Pediatr*. 2015;15:57.
3. Asti L, Magers JS, Keels E, Wispe J, McClead RE. A quality improvement project to reduce length of stay for neonatal abstinence syndrome. *Pediatrics*. 2015;135(6):e1494-1500.

# Drug use remains a problem in the US




***Enough opiate pain reliever prescriptions written for every American adult to have 1 bottle***



*Data from National Inpatient Sample developed by Agency for Healthcare Research & Quality's HCUP*

1. Wiles JR, Isemann B, Mizuno T, Tabangin ME, Ward LP, Akinbi H, et al. Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study. *J Pediatr.* 2015.
2. Patrick SW, Davis MM, Lehman CU, Cooper WO. Increasing incidence & geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. *J Perinatol.* 2015;35(8):667.
3. Patrick SW, Schumacher RE, Bennywort BD, Krans EE, McAllister JM, Davis MM. Neonatal Abstinence Syndrome & Associated Health Care Expenditures, United States, 2000-2009. *JAMA.* 2012. 307 (18): 1934-40.
4. Hall ES, Wexelblatt SL, Crowley M, Grow JL, Jasin LR, Klebanoff MA, et al. A multicenter cohort study of treatments & hospital outcomes in neonatal abstinence syndrome. *Pediatrics.* 2014;134(2):e527-534.

# More babies are experiencing NAS....




***“In 2012,  
the estimated  
number of  
newborns w/NAS  
was 21,732 or  
1 infant born every  
25 minutes...”***

*Data from Healthcare Cost & Utilization Project’s Kids’ Inpatient Database*

1. Patrick SW, Davis MM, Lehman CU, Cooper WO. Increasing incidence & geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. *J Perinatol.* 2015;35(8):667.
2. Patrick SW, Davis MM, Lehman CU, Cooper WO. Increasing incidence & geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. *J Perinatol.* 2015;35(8):667.
3. Hall ES, Wexelblatt SL, Crowley M, Grow JL, Jasin LR, Klebanoff MA, et al. Implementation of a Neonatal Abstinence Syndrome Weaning Protocol: A Multicenter Cohort Study. *Pediatrics.* 2015;136(4):e803-810.

# ...and are admitted to the NICU...



***NAS becoming responsible***

***for a growing portion of NICU resources nationwide***



# ...diagnosed with...

**Table 1.** Characteristics of infants with neonatal abstinence syndrome vs all other hospital births, 2012

	<i>Infants with neonatal abstinence syndrome (N = 21 732)</i>		<i>All other hospital births (N = 3 716 916)</i>		<i>P-value</i>
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	
Female	9902	45.6	1 817 513	48.9	< 0.001
<i>Clinical characteristics</i>					
Low birthweight	5308	24.4	267 885	7.2	< 0.001
<i>Respiratory diagnoses</i>					
Transient tachypnea	2552	11.7	113 483	3.1	< 0.001
Meconium Aspiration syndrome	613	2.8	13 235	0.4	< 0.001
Respiratory distress syndrome	977	4.5	74 001	2.0	< 0.001
Jaundice	7134	32.8	708 872	19.1	< 0.001
Feeding difficulty	3765	17.3	111 288	3.0	< 0.001
Seizures	309	1.4	4208	0.1	< 0.001
Sepsis	3218	14.8	81 845	2.2	< 0.001
<i>Insurance</i>					
Private	2688	12.4	1 717 308	46.2	< 0.001
Medicaid	17 717	81.5	1 726 432	46.4	
Uninsured	853	3.9	144 137	3.9	
Other	405	1.9	118 918	3.2	

Point estimate (standard error) *N* for NAS = 21 732 (857); unweighted sample *n* = 16 254. Point estimate (standard error) *N* for all other hospital births = 3 716 916 (55 864); unweighted sample *n* = 1 094 748.

# Healthcare burden of NAS

**Table 2.** Mean length of stay and inflation-adjusted hospital charges for all infants with neonatal abstinence syndrome, infants with neonatal abstinence syndrome with a length of hospital stay >6 days and uncomplicated term infants, 2009–2012

Year	2009 N (95% CI)	2010 N (95% CI)	2011 N (95% CI)	2012 N (95% CI)
<b>Neonatal abstinence syndrome</b>				
Mean length of stay (days)	16.5 (15.9–17.2)	17.2 (15.8–18.5)	16.6 (15.1–18.1)	16.9 (16.0–17.7)
Mean hospital charges (2012 US\$)	53 800 (49 400–58 300)	59 000 (49 600–68 400)	62 300 (52 900–71 700)	66 700 (61 800–71 600)
<b>Pharmacologically treated neonatal abstinence syndrome</b>				
Mean length of stay (days)	22.7 (21.9–23.4)	22.9 (21.6–24.1)	22.8 (21.5–24.2)	23.0 (22.2–23.8)
Mean hospital charges (2012 US\$)	75 700 (69 500–82 000)	80 500 (68 000–93 100)	87 700 (76 300–99 100)	93 400 (86 900–100 000)
<b>Uncomplicated term infant</b>				
Mean length of stay (days)	2.1 (2.1–2.1)	2.1 (2.1–2.1)	2.1 (2.1–2.1)	2.1 (2.1–2.1)
Mean hospital charges (2012 US\$)	2800 (2700–2900)	3500 (3300–3800)	3700 (3400–3900)	3500 (3400–3600)

Abbreviation: CI, confidence interval. All US\$ inflation adjusted to 2012 and rounded to nearest hundred.

***Despite awareness of NAS management issues, there has been little difference in length of stay....***

1. Patrick SW, Schumacher RE, Bennywort BD, Krans EE, McAllister JM, Davis MM. Neonatal Abstinence Syndrome & Associated Health Care Expenditures, United States, 2000-2009. *JAMA* 2012. 307 (18): 1934-40.
2. Patrick SW, Davis MM, Lehman CU, Cooper WO. Increasing incidence & geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. *J Perinatol*. 2015;35(8):667.
3. Hall ES, Wexelblatt SL, Crowley M, Grow JL, Jasin LR, Klebanoff MA, et al. Implementation of a Neonatal Abstinence Syndrome Weaning Protocol: A Multicenter Cohort Study. *Pediatrics*. 2015;136(4):e803-810.
4. Asti L, Magers JS, Keels E, Wispe J, McClead RE. A quality improvement project to reduce length of stay for neonatal abstinence syndrome. *Pediatrics*. 2015;135(6):e1494-1500.

# Why focus on LOS<sup>1</sup>?

***Often used as an indicator of efficiency***

- 👤 Medication errors
- 👤 Adverse events (e.g. CLABSI, VAP, pressure ulcers, SSE)
- 👤 Impaired parent-infant attachment
- 👤 Increased stress on families already stressed
- 👤 Increased financial burden on families & society

<sup>1</sup>LOS: Length of hospital stay

# Healthcare burden of NAS

**Table 2.** Mean length of stay and inflation-adjusted hospital charges for all infants with neonatal abstinence syndrome, infants with neonatal abstinence syndrome with a length of hospital stay >6 days and uncomplicated term infants, 2009–2012

Year	2009 N (95% CI)	2010 N (95% CI)	2011 N (95% CI)	2012 N (95% CI)
<i>Neonatal abstinence syndrome</i>				
Mean length of stay (days)	16.5 (15.9–17.2)	17.2 (15.8–18.5)	16.6 (15.1–18.1)	16.9 (16.0–17.7)
Mean hospital charges (2012 US\$)	53 800 (49 400–58 300)	59 000 (49 600–68 400)	62 300 (52 900–71 700)	66 700 (61 800–71 600)
<i>Pharmacologically treated neonatal abstinence syndrome</i>				
Mean length of stay (days)	22.7 (21.9–23.4)	22.9 (21.6–24.1)	22.8 (21.5–24.2)	23.0 (22.2–23.8)
Mean hospital charges (2012 US\$)	75 700 (69 500–82 000)	80 500 (68 000–93 100)	87 700 (76 300–99 100)	93 400 (86 900–100 000)
<i>Uncomplicated term infant</i>				
Mean length of stay (days)	2.1 (2.1–2.1)	2.1 (2.1–2.1)	2.1 (2.1–2.1)	2.1 (2.1–2.1)
Mean hospital charges (2012 US\$)	2800 (2700–2900)	3500 (3300–3800)	3700 (3400–3900)	3500 (3400–3600)

Abbreviation: CI, confidence interval. All US\$ inflation adjusted to 2012 and rounded to nearest hundred.

NOTE: Hospital charges do not equal hospital costs, & do not include professional fees.

## *Hospital charges for NAS continue to increase*

1. Patrick SW, Schumacher RE, Bennywort BD, Krans EE, McAllister JM, Davis MM. Neonatal Abstinence Syndrome & Associated Health Care Expenditures, United States, 2000-2009. *JAMA* 2012. 307 (18): 1934-40.
2. Patrick SW, Davis MM, Lehman CU, Cooper WO. Increasing incidence & geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. *J Perinatol*. 2015;35(8):667.
3. Patrick SW. The Triple Aim for Neonatal Abstinence Syndrome. *J Pediatr*. 2015.

***“We have to stop treating addiction as a moral failing, and start seeing it for what it is: a chronic disease that must be treated with urgency and compassion.”***

Dr. Vivek H. Murthy  
US Surgeon General

# We have an opioid crisis

Surgeon General's #TurnTheTide Campaign

**2 of 5 Americans say they personally know someone who has been addicted to prescription painkillers**


**No change in overall amount of pain that Americans report  
à 4x as many opioid prescriptions written since 1999**

**78 Americans die every day from opioid overdoses**



# Where is the NAS problem?


Neonatal Abstinence Syndrome per 1000 Hospital Births by US Census Division, 2012



*The incidence of NAS per 1000 hospital births as reported by the US census bureau geographic division.*

## Top 10 counties

1. Duval (450)
2. Hillsborough (324)
3. Pinellas (276)
4. Pasco (256)
5. Brevard (231)
6. Orange (219)
7. Volusia (201)
8. Sarasota (175)
9. Lee (173)
10. Manatee (170)




Data Source:  
Linked AHCA birth records and birth certificates  
ICD-9-CM codes: 779.5, 760.72



Monthly shelter report 4/2017	
# children in shelters	79
# children sheltered	140
Children in relative placement	41
Children in non-relative or foster placement	85

### Reasons for child removal from parent



**Age:**  
 35%: 0-1 years  
 27%: 2-5 years  
 23%: 6-10 years

Hillsborough County Sherriff's Office Child Protective Investigation Division. 4/2017 report.  
 2017 Policy Academy: Improving outcomes for pregnancy and postpartum women with opioid use disorders and their Infants, families, and caregivers.

# Healthcare burden of NAS

- ü Increased incidence of antenatal drug use
- ü Increased incidence of NAS
- ü Increased healthcare expenditures



## **Increase public health measures:**

- 👶 Reduce antenatal exposures
- 👶 Improve NAS management strategies



Office of Drug Control Policy

Social workers

Governor's office  
or Taskforce Representative

Inpatient & Outpatient  
**Pediatrics, Neonatology,  
Obstetrics, & Primary care**  
(Physicians ± trainees, NPs)

Psychosocial &  
environmental support  
services

*Medication assisted  
treatment facilities*

Maternal & Child Health  
Department/Public Health  
services

---

*Mother*

Medicaid or  
Private insurance

Lactation

A A P

Healthy Start  
Healthy Families

*Judicial systems*

**MENTAL HEALTH  
SERVICES**

Hospital  
Associations

**Early intervention  
programs**

**EARLY CHILDHOOD  
EDUCATION**


AHCA

Child welfare agencies,  
Child protection services,  
Child abuse prevention,  
Family reunification



**Table.** Applying *Crossing the Quality Chasm* improvement aims for improving care to infants with NAS


<b>Crossing the Quality Chasm aim</b>	<b>NAS example</b>
Safe	Minimizing risk from opioid administration, including decreasing total administration and appropriate monitoring.
Effective	Ensuring that all care practices are evidenced-based and eliminate practices not likely to yield benefit.
Patient-centered	Ensuring that, when possible, the maternal/infant dyad remains intact.
Timely	Ensuring that infants needing treatment (nonpharmacologic and pharmacologic) receive it without delay, minimizing exacerbation of their clinical signs.
Efficient	Reducing waste by eliminating unnecessary pharmacotherapy and excess length of hospital stay.
Equitable	Ensuring that infants with NAS and their families are treated just as other families in the neonatal intensive care units.



- Improve knowledge
- Standardize management
- Address attitudes

---


1. Patrick SW. The Triple Aim for Neonatal Abstinence Syndrome. *J Pediatr.* 2015.
2. Sikka R, Morath JM, Leape L. The Quadruple Aim: care, health, cost, & meaning in work. *BMJ Qual Saf.* 2015; 0:1-3.



---



1. Patrick SW. The Triple Aim for Neonatal Abstinence Syndrome. *J Pediatr.* 2015.
2. Sikka R, Morath JM, Leape L. The Quadruple Aim: care, health, cost, & meaning in work. *BMJ Qual Saf.* 2015; 0:1-3.

- Access to substance dependency treatment
- Limit high risk opioid prescribing practices
- Increase drug control systems



---

1. Patrick SW. The Triple Aim for Neonatal Abstinence Syndrome. *J Pediatr*. 2015.
2. Sikka R, Morath JM, Leape L. The Quadruple Aim: care, health, cost, & meaning in work. *BMJ Qual Saf*. 2015; 0:1-3.



• Improve population health

• Improved CLINICIAN experience

• Support research & QI initiatives

• Lower costs


• Improved PATIENT experience

- 
1. Patrick SW. The Triple Aim for Neonatal Abstinence Syndrome. *J Pediatr*. 2015.
  2. Sikka R, Morath JM, Leape L. The Quadruple Aim: care, health, cost, & meaning in work. *BMJ Qual Saf*. 2015; 0:1-3.




# Five-points Framework

## Substance Exposed Infants Framework



Antepartum care/  
Identify mother at risk (e.g.  
USF OB, USF Pediatrics, Addiction  
Medicine specialists [DACCO], Healthy  
Start coalition)

Hospital delivery



Identify infant of a  
substance abusing  
mother (ISAM)

Asymptomatic


NAS


Non-pharmacologic  
treatment

Pharmacologic  
treatment

Pediatrician

Discharge  
home





Opioids
morphine methadone buprenorphine oxycodone heroin

CNS depressants
benzodiazepines barbiturates

CNS stimulants
methamphetamines amphetamines SSRIs SNRIs

*\* Infants <34 wks GA or exposed to other substances may exhibit NAS symptoms*

# Main opportunities for improvement

- 👶 **Identify at risk infants**
- 👶 Optimize nonpharmacologic care
- 👶 Standardize pharmacologic management
- 👶 Comprehensive discharge planning



# Antenatal management

- Early identification of mothers at risk for drug abuse
  - Obtain maternal UDS<sup>1</sup>
  - Referral to drug treatment facility ASAP
  - Provide education, support, & conversion to alternative therapy (e.g., Medication-assisted treatment)
- Methadone maintained mothers (vs. heroin):
  - Higher access to prenatal care
  - Infants w/higher birth weight
  - Experience less pregnancy complications (e.g., preterm birth)

<sup>1</sup>UDS: Urine drug screen


1. Patrick SW, Davis MM, Lehman CU, Cooper WO. Increasing incidence & geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. *J Perinatol.* 2015;35(8):667.
2. Maguire D. Care of the infant with neonatal abstinence syndrome: strength of the evidence. *J Perinat Neonatal Nurs.* 2014;28(3):204-211; quiz E203-204.
3. Brown MS, Hayes MJ, Thornton LM. Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. *J Perinatol.* 2015;35(4):278-283.

# TGH<sup>1</sup> NAS parent pamphlet

- 👶 Education about NAS
- 👶 Discusses signs & symptoms
- 👶 Behavior-specific comforting techniques
- 👶 Patterns of activity
- 👶 Pharmacologic management

<sup>1</sup>TGH: Tampa General Hospital. USF neonatologists solely practice in the TGH NICU.

---



# Identify infants at risk

- Obtain UDS<sup>1</sup> w/in 24 hours of life
- Short term exposures (24-72 hrs from delivery)

## Risk factors

- Engaged In High Risk Behaviors
- Known H/O Drug Use Or Abuse
- Enrollment In Drug Treatment Facility
- Inadequate Or No Prenatal Care
- Previous Unexplained IUFD Or SIDS
- Placental Abrupton
- At Request Of Primary Physician/OB
- At request of Child Protective Services (i.e. open case, h/o child abuse, suspected domestic violence)

## TGH's standard UDS

Cannabinoids  
Cocaine  
Amphetamines  
Phencyclidine  
Barbiturates  
Benzodiazepines  
Opiates  
**Methadone**

\*Does not test oxycodone or buprenorphine (Subutex/Suboxone)

<sup>1</sup>UDS: Urine drug screen

# NAS symptoms

*Many babies exhibit withdrawal symptoms, but not all require pharmacologic therapy*

CNS

- High pitched cry
- Hyperirritability
- Tremors
- Increased muscle tone
- Sleep disturbances
- Seizures
- Skin excoriation

ANS

- Temp. elevation
- Sweating
- Tachypnea
- Nasal flaring
- Mottled color
- Sneezing
- Nasal stuffiness
- Yawning

GI

- Poor feeding
- Excessive sucking
- Emesis
- Weight loss
- Loose stools

## NAS symptoms

W

Wakefulness

I

Irritability

T

Temp. elevation  
Tremors/Seizures

H

Hyperactivity  
High pitched cry  
Hypertonicity

D

Diarrhea  
Disorganized sucking

R

Respiratory distress  
Rhinorrhea/nasal stuffiness  
Rub marks

1. Examining the evidence surrounding *Adv Neonatal Care*. 2014;14(3):181-186.
2. A quality improvement project to reduce *Pediatrics*. 2015;135(6):e1494-1500.
3. Maguire DJ, Rowe MA, Spring H, Elliott AF. Patterns of Disruptive Feeding Behaviors in Infants With Neonatal Abstinence Syndrome. *Adv Neonatal Care*. 2015.




# Finnegan Scoring

- ☺ Predominantly cue-related
- ☺ Only validated in:
  - ☺ Term & late preterm
  - ☺ Narcotic exposed
- ☺ Dynamic scoring
- ☺ Highest point value for items with greatest risk for adverse outcome

1. Orlando S. An overview of clinical tools used to assess neonatal abstinence syndrome. *J Perinat Neonatal Nurs.* 2014;28(3):212-219.
2. Ruwanpathirana R, Abdel-Latif ME, Burns L, Chen J, Craig F, Lui K, et al. Prematurity reduces the severity & need for treatment of neonatal abstinence syndrome. *Acta Paediatr.* 2015;104(5):e188-194.
3. Orlando S. An overview of clinical tools used to assess neonatal abstinence syndrome. *J Perinat Neonatal Nurs.* 2014;28(3):212-219.

SIGNS AND SYMPTOMS	SCORE
Excessive Cry	2 - 3
Sleeps < 1 hour after feeding	3
Sleeps < 2 hours after feeding	2
Sleeps < 3 hours after feeding	1
Hyperactive Moro Reflex	1
Markedly Hyperactive Moro Reflex	2
Mild Tremors: Disturbed	1
Moderate-Severe Tremors: Disturbed	2
Mild Tremors: Undisturbed	1
Moderate-Severe Tremors: Undisturbed	2
Increased Muscle Tone	1-2
Excoriation (specific area)	1 - 2
Generalized Seizure	8
Fever > 37.2 C	1
Frequent Yawning	1
Sweating	1
Nasal Stuffiness	1
Sneezing	1
Tachypnea (Respiratory Rate > 60/min)	2
Poor Feeding	2
Vomiting	2
Loose Stools	2
Failure to Thrive (weight gain $\geq$ 10% below birth weight)	2
Excessive Irritability	1 - 3
<b>TOTAL SCORE / CATEGORY</b>	

# Length of inpatient monitoring



- 55-94% of infants exposed to opioids in utero develop NAS symptoms<sup>2</sup>
- Mean time to onset: 46.1 hours (median 36 hours)<sup>3</sup>

1. Smirk CL, Bowman E, Doyle LW, Kamlin CO. How long should infants at risk of drug withdrawal be monitored after birth? *J Paediatr Child Health*. 2014;50(5):352-355.
2. Asti L, Magers JS, Keels E, Wispe J, McClead RE. A quality improvement project to reduce length of stay for neonatal abstinence syndrome. *Pediatrics*. 2015;135(6):e1494-1500.
3. Hall ES, Wexelblatt SL, Crowley M, Grow JL, Jasin LR, Klebanoff MA, et al. Implementation of a Neonatal Abstinence Syndrome Weaning Protocol: A Multicenter Cohort Study. *Pediatrics*. 2015;136(4):e803-810.

# Main opportunities for improvement

- 👶 Identify at risk infants
- 👶 **Optimize nonpharmacologic care**
- 👶 Standardize pharmacologic management
- 👶 Comprehensive discharge planning



# Nonpharmacologic management

*Should be standard of care for all at risk for NAS*

## **Goals:**

- 👶 Decrease symptoms
- 👶 Promote growth & weight gain
- 👶 Facilitate parental attachment & address staff attitudes







# Nonpharmacologic interventions

**Table 2. Nonpharmacologic interventions: characteristics of potentially helpful interventions for infants with NAS supported by expert opinion only<sup>16</sup>**

Intervention	Purpose/use
Decreased environmental stimuli Frequent small/demand feedings Holding	Room should be quiet, dimly lit, and use slow infant handling May help in infants with motor or tone dysregulation Infants who have poor motor control (thrashing or exaggerated rooting) respond to gentle head/limb restraint by helping them regulate
Nonnutritive sucking Swaddling	Helps organize a dysregulated infant and prevents disorganization Helps maintain regulation, self-soothe, and better tolerate stimulation (such as diaper change)
Containment Rubbing	Gentle containment or pressure supports motor and tone control Rubbing often better than patting when burping during feedings to avoid triggering Moro reflex
Vertical rocking	Facilitates relaxation and eye contact; more soothing than "regular" rocking or side to side.

## Other alternatives

-  Kangaroo care
-  Music therapy
-  Massage
-  Acupuncture
-  Non-oscillating water beds

# BF<sup>1</sup>, Methadone mothers, & the AAP

*BF<sup>1</sup> rates in methadone-maintained mothers  
are lower than the national average*

## AAP

- 👶 1983-2000: no BF<sup>1</sup> if methadone >20 mg/day
- 👶 2001: no dose restriction

***Benefits of BF<sup>1</sup> outweigh  
any theoretical minimal risk from excretion in breast milk***


- 👶 Barriers: mother, healthcare provider, community

<sup>1</sup>BF: Breastfeeding

- 
1. Hilton TC. Breastfeeding considerations of opioid dependent mothers & infants. *MCN Am J Matern Child Nurs.* 2012. 37(4): 236-40.
  2. Maguire D. Care of the infant with neonatal abstinence syndrome: strength of the evidence. *J Perinat Neonatal Nurs.* 2014;28(3):204-211; quiz E203-204.

# Facilitating parental attachment

## *Share information with parents*


- 👤 Discuss possibility of NAS & postnatal management w/parent  
*Symptom monitoring, length of stay, types of management*
  - 👤 Family centered rounds where daily goals & care plan are discussed
  - 👤 Inpatient NAS informational packets  
*TGH NAS parent pamphlet, Inpatient NAS magnet, Music CD*
  - 👤 Help parents interact with their infant:  
*OT: Individualized care plan & handouts*
- 
- 

# Inpatient NAS magnet

Symptoms to watch for: difficulty feeding, vomiting, diarrhea shakiness when resting, fast breathing, cranky behavior.

- 🌀 Erasable, magnetic tablet
- 🌀 Posted on whiteboard in patient room

## Goals:

- 🌀 Care plan
  - 🌀 Recognition of 6 NAS symptoms
  - 🌀 Routines
  - 🌀 Soothing techniques
- 
- 




# Staff attitudes

- 👤 Infant – Caregiver -- Medical team
- 👤 Nursing in-services
  - 👤 Provide education regarding substance abuse
  - 👤 Address staff attitudes & parent perceptions

***“You have the opportunity to impact someone’s life with education & words of encouragement or praise...”***

1. Doyle C, Lennox L, Bell D. A systematic review of evidence on the links between patient experience & clinical safety & effectiveness. *BMJ Open*. 2013; 3 (1) e001570.
2. Maguire D. Care of the infant with neonatal abstinence syndrome: strength of the evidence. *J Perinat Neonatal Nurs*. 2014;28(3):204-211; quiz E203-204.

# Main opportunities for improvement

- 👶 Identify at risk infants
  - 👶 Optimize nonpharmacologic care
  - 👶 **Standardize pharmacologic management**
    - 👶 Evaluation strategy
    - 👶 Initiation of pharmacologic treatment
    - 👶 Medications used (1<sup>st</sup> & 2<sup>nd</sup> line)
    - 👶 Escalation & weaning parameters
  - 👶 Comprehensive discharge planning
- 
- 

# Need a standardized protocol


*Most important predictors  
for LOS & duration of opioid treatment*

- 👤 Starting dose
- 👤 Escalation & weaning parameters
- 👤 Minimize ambiguity

***“...it is not easy to alter medical practices or clinician behavior,  
even when there is compelling evidence to do so...”***

1. Hall ES, Meinzen-Derr J, Wexelblatt SL. Cohort Analysis of a Pharmacokinetic-Modeled Methadone Weaning Optimization for Neonatal Abstinence Syndrome. *J Pediatr.* 2015.
2. Sarkar S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. *J Perinatol.* 2006;26(1):15-17.
3. Hall ES, Wexelblatt SL, Crowley M, Grow JL, Jasin LR, Klebanoff MA, et al. A multicenter cohort study of treatments & hospital outcomes in neonatal abstinence syndrome. *Pediatrics.* 2014;134(2):e527-534.

# Pharmacologic management for NAS



1. Tolia VN, Patrick SW, Bennett MM, Murthy K, Sousa J, Smith PB, Clark RH, Spitzer AR. Increasing incidence of the neonatal abstinence syndrome in the U.S. neonatal ICUs. *N Engl J Med.* 2015; 372(22):2118-26.
2. Asti L, Magers JS, Keels E, Wispe J, McClead RE. A quality improvement project to reduce length of stay for neonatal abstinence syndrome. *Pediatrics.* 2015;135(6):e1494-1500.

# Main opportunities for improvement

- 👶 Identify at risk infants
- 👶 Optimize nonpharmacologic care
- 👶 Standardize pharmacologic management
- 👶 **Comprehensive discharge planning**



# Discharge planning


- Length of stay is minimum **5-7 days**

Drug	Recommended length of stay
SSRI	5 days
Non-opioid	5-7 days
Opioid	7 days

Hudak M, et al. *Pediatrics*, 2012.

- USF Pediatrics: outpatient methadone management
  - Clonidine is not an outpatient medication at USF/TGH

# Safe plan of care w/methadone

- Methadone may be considered if:
    - Social services clearance
    - Tolerating full oral feeds easily for caregiver
    - Appropriate weight gain
    - On a once daily dose of methadone  $<0.15$  mg/kg/dose
    - Consistent scores  $\leq 5$  for 48-72 hours
  - Parents have demonstrated:
    - Care for, soothing, & feeding of infant
    - Education regarding NAS symptoms
    - Methadone: dosing, administration, & storage
  - Other issues:
    - Support system assessment, feeding, consults (OT, lactation), Pediatrician, Early intervention services, community resources
- 
- 

- ☺ Method for caregiver to observe & record 6 NAS symptoms
- ☺ Should bring this to all Pediatric appointments

Health Start Coalition of Hillsborough County

**WEEK 1**

Date:			Weight:			Dose (ml):			Last ↑ or ↓:			Next appointment:			New medication dose (ml):			
Difficulty feeding			Vomiting			Diarrhea			Shakiness when resting			Fast breathing			Cranky behavior			
No	Some	Big	No	Some	Big	No	Some	Big	No	Some	Big	No	Some	Big	No	Some	Big	
Monday																		
Tuesday																		
Wednesday																		
Thursday																		
Friday																		
Saturday																		
Sunday																		
Comments:																		




# Who are our patients?

	Nonpharmacologic	Pharmacologic
%(n)	17% (27)	83% (128)
Male, %(n)	63% (100)	
GA (wks)	38 ± 1.5	
BW (g)	3006 ± 478	

**159 NAS patients**  
discharged from TGH NICU  
from 10/1/12 to 1/31/15

## Maternal Urine Drug Screen results in NAS infants



\*Total does not equal 100% as polysubstance abuse occurred in mothers  
\*Other refers to: PCP, Cocaine, Barbiturates, & Amphetamines

# USF's Quality Improvement initiative

- 👤 Improved consistency of care
  - 👤 Increased infants benefiting from improved intensive non-pharmacologic management
  - 👤 Decreased number of infants requiring outpatient pharmacologic management
- 👤 Decreased average LOS in those receiving pharmacologic management by 69% (avoiding ~20 hospital days)



# LOS<sup>1</sup> & Healthcare costs

	Outcome measures						
	0	1	2	3	4	5	6
LOS <i>all</i> infants, average (SD)	29 (21)	16 (12)	19 (16)	23 (16)	21 (15)	10 (8)	9 (8)

<sup>1</sup>LOS: Length of stay defined as the difference between date of NICU admission & date of NICU discharge

N=159

Average of 20 days saved per patient

Total days saved = 159 patients x 20 days = 3,180 days

- Patrick et al: Average cost for NAS patients ~\$3,337.50/day
- Potential cost savings= \$3,337.50 x 3,180 = \$10,613,250

# Approach to Quality Improvement

**International**  
(e.g., VON)

**State**  
(e.g., Ohio Perinatal Quality Collaborative)

**Hospital/Institution**  
(e.g., USF NICU)

***Is one approach better than another?***

---



# Goal of most collaboratives

- 👤 Meet challenges of growing demands & limited resources
- 👤 Increase ability to quickly implement evidence-based treatments & improvement methods
- 👤 Provide infrastructure
- 👤 Common approaches:
  - 👤 Guideline implementation strategies
  - 👤 Collaborative breakthrough method

**All** of Florida's mothers and infants will have the **best health outcomes** possible through receiving **high quality evidence-based** perinatal **care**.

## FPQC's Mission

Advance perinatal health care quality and patient safety for all of Florida's mothers and infants through the **collaboration of FPQC stakeholders** in the development of **joint quality improvement initiatives**, the advancement of **data-driven best practices** and the promotion of **education and training**.

# FPQC Partners and Funders

- Florida Health
- Agency for Health Care Administration (AHCA)
- Council on Patient Safety in Women's Health Care
- AWHONN Florida Promoting the Health of Women and Newborns
- Florida Affiliate of the American College Nurse-Midwives With women, for a lifetime®
- The American College of Obstetricians and Gynecologists Women's Health Care Physicians
- Florida Hospital Association
- Florida Society of Neonatologists
- March of Dimes®
- Florida Blue Cross Blue Shield
- Preeclampsia Foundation

# FPQC Initiatives

	2011	2012	2013	2014	2015	2016
Early Elective Delivery						
Neonatal Catheter Infections						
Obstetric Hemorrhage						
Golden Hour						
Antenatal Steroids						
Hypertension in Pregnancy						
Mothers Own Milk in NICU						
Perinatal QI Indicators						

**Next Infant Health Initiative is NAS**

1/2017: Planning phase

6/2017: Projected start




## *To help these mothers & infants*

- What can we do?
- What should we do?
- How can we work together?



# Opportunities

- 👶 Geographic variation of NAS
  - 👶 Interventions to
    - 👶 Decrease prevalence
    - 👶 Decrease Infant mortality, SUIDs, Child abuse
    - 👶 Increase early identification
    - 👶 Promote safe sleep
    - 👶 Smoking/Alcohol cessation
  - 👶 Medication-assisted treatment
  - 👶 Inter-conception care
  - 👶 Communicating between hospital & community partners
  - 👶 Best place to care for NAS
    - 👶 Inpatient vs. Outpatient
    - 👶 NICU vs. Special care nursery vs. Pediatric floor
  - 👶 Improve consistency & quality
  - 👶 Measurement for NAS severity
  - 👶 Decrease length of stay
  - 👶 Infant “Plan of Safe Care”
  - 👶 Coordinating post-discharge supportive services (support groups, counseling, home visits, housing services, infant follow-up services)
  - 👶 Developmental outcomes
- 
- 

# Thank you to the interdisciplinary team!

## **Medical team**

Terri Ashmeade, MD, HBIC

Mary Meiron, NP

Karen Fugate, BSN, RNC-NIC, CPHQ

Anita Smith, MSN, ARNP-BC

## **Pediatricians:**

Carol Lilly, MD

Luis Maldonado, MD

## **TGH administration**

Pam Sanders, RNC-NIC, MSN, CENP

Gloribel Medina, RNC-NIC, MHA, MPH

## **Contact info:**

[mbalakri@health.usf.edu](mailto:mbalakri@health.usf.edu)

Office #813-844-3437

## **Nurses**

Maria Arnobit

Jane Fox

Dea Holt

Karen Leonard

Beatrice Leviner

Susan Taylor

Dorothy Walsh

## **Healthy Start coalition**

of Hillsborough county

## **Social work:**

Robin Warnberg, MSW, LCSW

## **Antenatal:**

USF Department of OB

USF Department of Pediatrics

DACCO (Jason Fields, MD)

## **Pharmacy:**

Christy Bassel, PharmD

Saamil Patel, PharmD, BCPS

## **OT:**

Diane Allen, OTR-L

## **Lactation:**

Ivonne Hernandez, IBCLC

Leslie Turner, IBCLC

Patricia Hanning, IBCLC

---

Potential future team members: Parents